Sandoz Receives Certification for Transparent Practices
In a ceremony headed by Dr. Juan Francisco Millán Soberanes, CEO of CETIFARMA and Mtro. Marco Iván Escotto Arroyo, executive secretary; The agency delivered said certificate to Enrique Liñero, Country Head of Sandoz Mexico, whom the company’s steering committee accompanied.
“It is an honor for Sandoz México to receive from CETIFARMA the “Certificate of Company with Transparent Practices,” a distinction that endorses us as a company that operates day by day with adherence to ethics and transparency, values of the utmost importance in our industry, since they guarantee good practices that benefit the patients we serve, as well as the health personnel and institutions with which we collaborate,” commented Enrique Liñero, Country Head of Sandoz Mexico.
It is noteworthy that it is the first time that Sandoz Mexico has obtained this distinction as an independent company since it was previously awarded it by the pharmaceutical company Novartis.
“I trust that this recognition reinforces in each one of the members of the community their conviction of conducting themselves with integrity, transparency, and above all, that they feel proud to belong to a company that respects the laws and is worthy of the trust of the companies. Authorities and the general public for their ethical and transparent actions”, commented Dr. Juan Francisco Millán, General Director of CETIFARMA.
“Sandoz receives this certificate with satisfactory adherence to 12 of the 12 standards considered, obtaining a high rating in 176 of 182 indicators; the certification process also included indicators of the National Anticorruption System”, concluded Dr. Millán.
Sandoz is an ally for health systems in the world and Mexico, making it possible for millions of patients to access innovative treatments that improve their quality of life. In addition, it is the No. 1 biosimilar company globally and a pioneer in developing this innovative therapy, which uses cells to transport the treatment through the body. This degree of innovation, coupled with its solid corporate practices, makes Sandoz an ideal ally to ensure the health of millions of patients.
The major issues for the further development of the pharmaceutical market will be discussed at the Mexican Pharmaceutical Forum that will be organized by the Global Pharmaceutical Leaders’ Club on the 29-30th November 2022 in Mexico City. Secure your delegate place ASAP! Registration is here: https://mexicanpharmaforum.com/registration/
Takeda appoints Hernán Porcile as its new General Manager in Mexico
October 24, 2022
Solid growth of the Medical Devices sector in Mexico
October 19, 2022
UCB Celebrates 25 Years in Mexico and Inaugurates New Offices
October 18, 2022